Substance use disorders: Realizing the promise of pharmacogenomics and personalized medicine

Annual Review of Clinical Psychology

Volumn 6, Issue , 2010, Pages 577-589

  Hutchison, Kent E ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Addiction; Brain; Endophenotypes; Genetics; Treatment

Indexed keywords

ARIPIPRAZOLE; NALTREXONE; OLANZAPINE; ONDANSETRON; TOPIRAMATE;

BRAIN DEVELOPMENT; COGNITION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; GENE REPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN GENOME; INTERVIEW; PHARMACOGENOMICS; PHENOTYPE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUBSTANCE ABUSE;

GENOME, HUMAN; HUMANS; PATIENT-CENTERED CARE; PHARMACOGENETICS; SUBSTANCE-RELATED DISORDERS;

EID: 77952916178     PISSN: 15485943     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.clinpsy.121208.131441     Document Type: Review

References (68)

1. Adinoff B, Junghanns K, Kiefer F, Krishnan-Sarin S. 2005. Suppression of the HPA axis stress-response: implications for relapse. Alcohol Clin. Exp. Res. 29:1351-1355
2. Anton RF. 2008. Naltrexone for the management of alcohol dependence. N. Engl. J. Med. 359:715-721
3. Anton RF, O'Malley SS, Ciraulo DA, Couper D, Gastfriend DR, et al. 2006. Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence. The COMBINE study: a randomized controlled trial. JAMA 295:2003-2017
4. Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, et al. 2008. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch. Gen.Psychiatry 65:135-144
5. Arranz MJ, de Leon J. 2007. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry 12(8):707-747
6. Arranz MJ, Kapur S. 2008. Pharmacogenetics in psychiatry: Are we ready for widespread clinical use? Schizophr. Bull. 34 1130-1144
7. Baler RD, Volkow ND. 2006. Drug addiction: the neurobiology of disrupted self-control. Trends Mol. Med. 12(12):559-566
8. Bechara A. 2005. Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nat. Neurosci. 8:1458-1463
9. Begleiter H, Porjesz B. 2006. Genetics of human brain oscillations. Int. J. Psychophysiol. 60:162-171
10. Berridge KC, Robinson TE. 1998. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res. Brain Res. Rev. 28:309-369
11. Bickel WK, Miller ML, Yi R, Kowal BP, Lindquist DM, Pitcock JA. 2007. Behavioral and neuroeconomics of drug addiction: competing neural systems and temporal discounting processes. Drug Alcohol Depend. 90S:S85-91
12. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, et al. 2007. Novel genes identified in a highdensity genome wide association study for nicotine dependence. Hum. Mol. Genet. 16:24-35
13. Cannon TD, Keller MC. 2006. Endophenotypes in the genetic analyses of mental disorders. Annu. Rev. Clin. Psychol. 2:267-290
14. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, et al. 2007. Replicating genotype-phenotype associations. Nature 447:655-660
15. Chen AC, Tang Y, Rangaswamy M, Wang JC, Almasy L, et al. 2009. Association of single nucleotide polymorphisms in a glutamate receptor gene (GRM8) with theta power of event-related oscillations and alcohol dependence. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B: 359-368
16. Chen AC, Tang Y, Rangaswamy M,Wang JC, Almasy L, et al. 2009. Association of single nucleotide polymorphisms in a glutamate receptor gene (GRM8) with theta power of event-related oscillations and alcohol dependence. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B:359-368
17. Esslinger C,Walter H, Kirsch P, Erk S, Schnell K, et al. 2009. Neural mechanisms of a genome-wide supported psychosis variant. Science 324:605
18. Feldstein Ewing SW, LaChance HA, Bryan A, Hutchison KE. 2009. Do genetic and individual risk factors moderate the efficacy of motivational enhancement therapy? Drinking outcomes with an emerging adult sample. Addict. Biol. 14:356-365
19. Filbey FM, Claus E, Audette AR, Niculescu M, Banich MT, et al. 2008a. Exposure to the taste of alcohol elicits activation of the mesocorticolimbic neurocircuitry. Neuropsychopharmacology 33:1391-1401
20. Filbey FM, Ray L, Smolen A, Claus ED, Audette A, Hutchison KE. 2008b.Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin. Exp. Res. 32:1113-1123
21. Filbey FM, Slack KJ, Sunderland TP, Cohen RM. 2006. Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEepsilon4 in young healthy adults. Neuroreport 17:1585-1590
22. Garavan H, Pankiewicz J, Bloom A, Cho JK, Sperry L, et al. 2000. Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am. J. Psychiatry 157:1789-98
23. George DT, Gilman J, Hersh J, Thorsell A, Herion D, et al. (2008). Neurokinin 1 receptor antagonism as apossible therapy for alcoholism. Science 319(5869):1536-1539
24. Glahn DC, Paus T, Thompson PM. 2007. Imaging genomics: mapping the influence of genetics on brain structure and function. Hum. Brain Mapp. 28:461-463
25. Goldstein RZ, Alia-Klein N, Tomasi D, Carrillo JH, Maloney T, et al. 2009. Anterior cingulate cortex hypoactivations to an emotionally salient task in cocaine addiction. Proc. Natl. Acad. Sci. USA 106:9453-9458
26. Goldstein RZ, Volkow ND. 2002. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am. J. Psychiatry 159:1642-52
27. Gottesman II, GouldTD.2003. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 160:636-645
28. Hardy J, Singleton A. 2009. Genomewide association studies and human disease. N. Engl. J. Med. 360:1759-1768
29. Hariri AR,Weinberger DR. 2003. Imaging genomics. Br. Med. Bull. 65:259-270
30. Heinz A, Friedel E, Muller DJ, Puls I, Wrase J. 2007. Genetic research with intermediate phenotypes: phenocopies, perspectives and pitfalls. Addiction 102:1696-1697
31. Hirschhorn JN. 2009. Genomewide association studies-illuminating biologic pathways. N. Engl. J. Med. 360:1699-1701
32. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. 2002. A comprehensive review of genetic association studies. Genet. Med. 4:45-61
33. Hughes AR, Brothers CH, Mosteller M, Spreen WR, Burns DK. 2009. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example. Pharmacogenomics 10(2):225-233
34. Hutchison KE, Allen DL, Filbey FM, Jepson C, Lerman C, et al. 2007. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch. Gen. Psychiatry 64:1078-1086
35. Hutchison KE, Haughey H, Niculescu M, Schacht J, Kaiser A, et al. 2008. The incentive salience of alcohol: translating the effects of genetic variant in CNR1. Arch. Gen. Psychiatry 65:841-850
36. Hutchison KE, Ray L, Sandman E, Rutter MC, Peters A, et al. 2006. The effect of olanzapine on craving and alcohol consumption. Neuropsychopharmacology 31:1310-1317
37. Hutchison KE,Wooden A, Swift RM, Smolen A, McGeary J, et al. 2003. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 28:1882-1888
38. Ioannidis JP. 2007. Non-replication and inconsistency in the genome-wide association setting. Hum. Hered. 64:203-213
39. Johnson BA, Roache JD, Ait-Daoud N, Zanca NA, Velazquez M. 2002. Ondansetron reduces the craving of biologically predisposed alcoholics. Psychopharmacology (Berl.) 160:408-413
40. Kalivas PW, Volkow ND. 2005. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry 162:1403-1413
41. Kenna GA, McGeary JE, Swift RM. 2004. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. Am. J. Health Syst. Pharm. 61:2380-2388
42. Khoury MJ, Bertram L, Boffetta P, Butterworth AS, Chanock SJ, et al. 2009. Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am. J.Epidemiol. 170:269-279
43. Komanduri R. 2003. Two cases of alcohol craving curbed by topiramate. J. Clin. Psychiatry 64:612
44. Koob GF, Le Moal M. 2001. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24:97-129
45. Kraft P, Hunter DJ. 2009. Genetic risk prediction-are we there yet? N. Engl. J. Med. 360:1701-1703
46. La RP, Corbin AS, Stoffregen EP, Deininger MW, Druker BJ. 2002. Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res. 62:7149-7153
47. Leland DS, Arce E, Miller DA, Paulus MP. 2008. Anterior cingulate cortex and benefit of predictive cueing on response inhibition in stimulant dependent individuals. Biol. Psychiatry 63:184-190
48. Mann K, Kiefer F, Smolka M, Gann H, Wellek S, Heinz A. 2009. Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. Alcohol Clin. Exp. Res. 33:674-683
49. McClernon FJ, Hutchison KE, Rose JE, Kozink RV. 2007. DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues. Psychopharmacology (Berl.) 194:433-441
50. McCrady BS. 2004. To have but one true friend: implications for practice of research on alcohol use disorders and social network. Psychol. Addict. Behav. 18:113-121
51. Miller WR, Walters ST, Bennett ME. 2001. How effective is alcoholism treatment in the United States? J. Stud. Alcohol 62:211-220
52. O'Donovan MC, Craddock N, Norton N,Williams H, Peirce T, et al. 2008. Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat. Genet. 40:1053-1055
53. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, et al. 2003. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546-1552
54. Piccart M, Lohrisch C, Di Leo A, Larsimont D. 2001. The predictive value of HER2 in breast cancer. Oncology 61:73-82 (Pubitemid 33033428)
55. Potenza MN.2007 .To do or not to do? The complexities of addiction, motivation, self-control, and impulsivity. Am. J. Psychiatry 164:4-6
56. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, et al. 2009. Commonpolygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460:748-752
57. Ramchandani V, Umhau J, Jones C, Issa J, Kerich M, et al. 2009. OPRM1 A118G polymorphism and alcoholinduced striatal dopamine release: an alcohol CLAMP/PET study. Alcohol Clin. Exp. Res. 33:260a (Abstr.)
58. Ray LA, Hutchison KE. 2007. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch. Gen. Psychiatry 64:1069-1077
59. Saccone SF, Hinrichs AL, Saccone NL, Chase GA, Konvicka K, et al. 2007a. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 16:36-49
60. Saccone SF, Pergadia ML, Loukola A, Broms U, Montgomery GW, et al. 2007b. Genetic linkage to chromosome 22q12 for a heavy-smoking quantitative trait in two independent samples. Am. J. Hum. Genet. 80:856-866
61. Seneviratne C, Huang W, Ait-Daoud N, Li MD, Johnson BA. 2009. Characterization of a functional polymorphism in the 3- UTR of SLC6A4 and its association with drinking intensity. Alcohol Clin. Exp. Res. 33:332-339
62. Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, et al. 2009. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460:753-757
63. Sinha R. 2008. Chronic stress, drug use, and vulnerability to addiction. Ann. N. Y. Acad. Sci. 1141:105-130
64. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, et al. 2009. Common variants conferring risk of schizophrenia. Nature 460:744-747
65. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, et al. 2008. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452:638-642
66. Visscher PM. 2008. Sizing up human height variation. Nat. Genet. 40:489-490
67. Volkow ND, Fowler JS. 2000. Addiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex. Cereb. Cortex 10:318-325
68. Weedon MN, Lango H, Lindgren CM,Wallace C, Evans DM, et al. 2008. Genome-wide association analysis identifies 20 loci that influence adult height. Nat. Genet. 40:575-583